Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 12/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15917383 | 1.00 | PYGL (0.47) | PYGLHPGDDHODHGRIN1GRIN2B | |
| SCHEMBL6077948 | 0.79 | LIPG (0.45) | PYGLGRIN1GRIN2B | |
| SCHEMBL6077635 | 0.78 | TSHR (0.49) | HPGDMEN1LMNAKMT2A | |
| SCHEMBL6077638 | 0.78 | TSHR (0.49) | HPGDMEN1LMNAKMT2A | |
| SCHEMBL14833023 | 0.72 | TAAR1 (0.50) | HPGDLMNAMAPT | |
| SCHEMBL14833022 | 0.72 | TAAR1 (0.50) | HPGDLMNAMAPT | |
| SCHEMBL14833096 | 0.69 | LIPG (0.46) | HPGDKCNH2MEN1LMNAKMT2A | |
| SCHEMBL14833095 | 0.69 | LIPG (0.46) | HPGDKCNH2MEN1LMNAKMT2A | |
| SCHEMBL6077313 | 0.66 | USP30 (0.47) | — | |
| SCHEMBL6077308 | 0.66 | USP30 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760829-B1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2760829-B1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9120794-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120794-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120794-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150105378-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105378-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105378-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-16 | — | — | US | disclosed |
| US-8952180-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952180-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952180-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140221357-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221357-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221357-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2760829-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013048982-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013048982-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221357-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | LIPG, LPL, PNLIP | PYGL 484/4885HPGD 690/4885DHODH 1048/4885 |
| US-20150105378-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | LIPG, PNLIP, LPL | PYGL 310/4885HPGD 567/4885DHODH 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.